Epigenomics AG / Key word(s): Study/Study results 08.05.2015 09:04 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. ————————————————————————— Epigenomics Reaches 99.5 % Adherence for Epi proColon(R) in ADMIT Study Berlin, Germany, […]
Category: Insider Information
08. December 2014
Ad hoc Announcement Pursuant to § 15 WpHG (German Securities Trading Act): Epigenomics and BioChain Announce Approval of Epi proColon(R) in China
Epigenomics AG / Key word(s): Regulatory Approval/Miscellaneous 08.12.2014 08:05 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. ————————————————————————— Berlin (Germany), Germantown, MD, and Newark, CA (U.S.A.), Beijing (China), December 08, 2014 […]
16. October 2014
Ad hoc Announcement Pursuant to § 15 WpHG (German Securities Trading Act): Epigenomics raises USD 5.3 million from its strategic commercialization partner BioChain
Epigenomics AG / Key word(s): Capital Increase/Miscellaneous 16.10.2014 09:30 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. ————————————————————————— Berlin (Germany) and Germantown (USA), October 16, 2014 – Epigenomics AG (ISIN: DE000A11QW50, […]
02. June 2014
Ad hoc Announcement Pursuant to § 15 WpHG (German Securities Trading Act): FDA Issues Response Letter for Epigenomics’ Colorectal Cancer Screening Blood Test Epi proColon(R) Requesting Further Data Pre-Approval
Epigenomics AG / Key word(s): Miscellaneous 02.06.2014 21:30 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP – a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. ————————————————————————— Berlin (Germany) and Germantown, MD (U.S.A.), June 2, 2014 – Epigenomics AG (ISIN: DE000A1K0516, […]
24. April 2014
Ad hoc Announcement Pursuant to § 15 WpHG (German Securities Trading Act): Epigenomics’ Partner BioChain Successfully Completes Clinical Validation Study for CFDA Approval of Epi proColon(R) in China
Epigenomics AG / Key word(s): Study/Miscellaneous 24.04.2014 12:10 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP – a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. ————————————————————————— Berlin (Germany), Germantown, MD, and Newark, CA (U.S.A.), Beijing (China), April 24, 2014 – […]
27. March 2014
Ad hoc Announcement Pursuant to § 15 WpHG (German Securities Trading Act) Epigenomics AG: FDA Advisory Committee Provides Recommendations for Epigenomics’ Colorectal Cancer Screening Blood Test
Epigenomics AG / Key word(s): Miscellaneous 27.03.2014 02:20 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP – a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. ————————————————————————— FDA Advisory Committee votes favorably that the benefits of Epi proColon(R) outweigh the risks […]